TARS MEXC RealStocks
Own real TARS shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-14 01:33:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Tarsus Pharmaceuticals, Inc. (TARS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $80.26, with a market capitalization of $3.79B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $53.89 to $91.53. This page covers its latest market performance, valuation, price trends and company information.
$3.79B | |
$76.79 | |
$81.16 | |
$76.01 | |
$76.89 | |
621.32K | |
871.99K | |
-- | |
$91.53 | |
$53.89 | |
-- | |
-- |
Tarsus Pharmaceuticals, Inc. (TARS) last closed at $80.26 as of 2026-11-14 00:31:00, up 4.38% ($3.36) from the previous close of $76.89.
During the latest regular trading session, TARS traded between $76.01 and $81.16, with a volume of 621.32K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Tarsus Pharmaceuticals, Inc. (TARS) moved from $69.07 to $80.26, representing a gain of 16.20% ($11.19).
The stock traded between $65.34 and $81.16 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1.21 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 70.1%
TARS is currently trading at $80.26, placing it 70.1% of the way from its 52-week low of $53.89 to its 52-week high of $91.53. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 370 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tarsus Pharmaceuticals, Inc. (TARS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to TARS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between TARS shares and USD.
TARS Shares to USD
1.00 TARS shares = 80.258 USD
Calculations are estimates based on the latest available price and are for reference only.